BioCryst reports more revenue, smaller loss than Street expectations
BioCryst Pharmaceuticals reports a loss of $2.6 million in its fourth quarter. But its financials topped Wall Street expectations.
Copy and paste this URL into your WordPress site to embed
Copy and paste this code into your site to embed
